Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company
Executive Summary
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
You may also be interested in...
Pharma Companies Urged To Stop In-Person Speaker Programs In HHS OIG ‘Special Fraud Alert’
Companies should consider alternatives to in-person physician presentations given the risk of kickback violations, OIG says. Concerns addressed in Novartis corporate integrity agreement are broader than that case, Chief Counsel to the Inspector General Greg Demske explains in an interview.
Closing The Books On Purdue – And US FDA’s Policies To Control Opioids
A massive settlement of opioid litigation is intended to end the era of opioid marketing defined by OxyContin. It also like closes the books on efforts to rely on the US FDA to control the prescription abuse crisis.
Infographic: A Decade Of Opioid Lawsuits And Settlements
A timeline of the history of opioid litigation from Purdue Pharma's 2007 settlement to the bellwether trial in Ohio.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: